Insmed Inc (INSM)vsPHAXIAM Therapeutics S.A. (PHXM)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PHXM
PHAXIAM Therapeutics S.A.
$3.10
0.00%
HEALTHCARE · Cap: $28.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 10054% more annual revenue ($606.42M vs $5.97M). PHXM leads profitability with a -1.9% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PHXM
Avoid11
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -38.6% — below average capital efficiency
Revenue declined 66.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PHXM
The strongest argument for PHXM centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PHXM
The primary concerns for PHXM are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
PHXM carries more volatility with a beta of 1.96 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
PHXM generates stronger free cash flow (-13M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 11/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
PHAXIAM Therapeutics S.A.
HEALTHCARE · BIOTECHNOLOGY · USA
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. The company is headquartered in Lyon, France.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?